Drug Trial Radar · NCT06132958
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
710
Planned (sponsor's estimate)
Start
Dec 6, 2023
Primary completion
Jan 10, 2028
Study completion Jan 10, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
- First posted
- Nov 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.
Conditions
- Endometrial Cancer
Interventions
Sacituzumab tirumotecanBiological
4 mg/kg of sacituzumab tirumotecan by IV infusion
DoxorubicinDrug
60 mg/m\^2 of doxorubicin by IV Infusion
PaclitaxelDrug
80 mg/m\^2 of paclitaxel by IV infusion
Nab-paclitaxelDrug
100 mg/m\^2 of nab-paclitaxel by IV infusion
Rescue medicationsDrug
Participants will receive the following rescue medications per approved product label before sacituzumab tirumotecan infusion: Histamine-1 (H1) receptor antagonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent, and steroid mouthwash (dexamethasone or equivalent).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 27 months
- Overall Survival (OS)Time frame: Up to approximately 48 months
Locations
242 sites in 31 countries. Site status is shown where the registry gives one.
USA Mitchell Cancer Institute ( Site 4142)
Mobile, Alabama
Alaska Womens Cancer Care ( Site 4122)
Anchorage, Alaska
HonorHealth (HH) ( Site 8000)
Phoenix, Arizona
Arizona Oncology Associates - HOPE ( Site 8002)
Tucson, Arizona
UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc ( Site 4131)
Los Angeles, California
California Pacific Medical Center - Van Ness Campus ( Site 4129)
San Francisco, California
Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 4114)
New Haven, Connecticut
MedStar Washington Hospital Center ( Site 4108)
Washington D.C., District of Columbia
Mount Sinai Cancer Center ( Site 4117)
Miami Beach, Florida
AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 4113)
Orlando, Florida
Florida Cancer Specialists - East ( Site 7000)
West Palm Beach, Florida
Northside Hospital ( Site 4112)
Atlanta, Georgia
Augusta University ( Site 4116)
Augusta, Georgia
Centricity Research Columbus Cancer Center ( Site 4154)
Columbus, Georgia
NorthShore University HealthSystem - Evanston Hospital ( Site 4110)
Evanston, Illinois
Parkview Research Center at Parkview Regional Medical Center ( Site 4132)
Fort Wayne, Indiana
Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 4150)
Edgewood, Kentucky
University Medical Center New Orleans ( Site 4133)
New Orleans, Louisiana
TRIALS 365 ( Site 4105)
Shreveport, Louisiana
University of Massachusetts Memorial Medical Center ( Site 4103)
Worcester, Massachusetts
Washington University School of Medicine-Obstetrics & Gynecology ( Site 4146)
St Louis, Missouri
The Center of Hope ( Site 4109)
Reno, Nevada
John Theurer Cancer Center at Hackensack University Medical Center ( Site 4118)
Hackensack, New Jersey
Atlantic Health System Morristown Medical Center ( Site 4135)
Morristown, New Jersey
Holy Name Medical Center ( Site 4115)
Teaneck, New Jersey
New York - Presbyterian Brooklyn Methodist Hospital ( Site 4134)
Brooklyn, New York
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 4156)
Mineola, New York
Laura and Isaac Perlmutter Cancer Center ( Site 4106)
New York, New York
Icahn School of Medicine at Mount Sinai-Department of Obstetrics, Gynecology, and Reproductive Scie ( Site 4128)
New York, New York
Good Samaritan Hospital Medical Center ( Site 4139)
West Islip, New York
Duke Cancer Institute ( Site 4120)
Durham, North Carolina
Sanford Health Roger Maris Cancer Center ( Site 4158)
Fargo, North Dakota
University of Cincinnati Medical Center ( Site 4136)
Cincinnati, Ohio
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C (Site 4125)
Columbus, Ohio
Sidney Kimmel Cancer Center - Jefferson Health ( Site 4157)
Philadelphia, Pennsylvania
AHN West Penn Hospital-Gynecologic Oncology ( Site 4111)
Pittsburgh, Pennsylvania
Asplundh Cancer Pavilion ( Site 4107)
Willow Grove, Pennsylvania
Women & Infants Hospital ( Site 4138)
Providence, Rhode Island
Sanford Cancer Center-Gynecologic Oncology ( Site 4121)
Sioux Falls, South Dakota
The West Clinic, PLLC dba West Cancer Center ( Site 4102)
Germantown, Tennessee
Showing 40 of 242 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.